v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 6,757 $ 7,778
General and administrative 3,845 2,958
Total operating expenses 10,602 10,736
Loss from operations (10,602) (10,736)
Other (expense) income    
Change in fair value of warrant liabilities (984) (507)
Foreign exchange transaction gain 13 0
Interest income 157 210
Interest expense (407) (176)
Total other expense, net (1,221) (473)
Net loss (11,823) (11,209)
Other comprehensive income:    
Foreign currency translation adjustment 5 31
Comprehensive loss $ (11,818) $ (11,178)
Net loss per common share, basic (in dollars per share) $ (0.65) $ (0.87)
Net loss per common share, diluted (in dollars per share) $ (0.65) $ (0.87)
Weighted average common shares and pre-funded warrants outstanding, basic (in shares) 18,211,745 12,950,574
Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) 18,211,745 12,950,574